Epitalon and Telomerase: What Longevity Research Actually Says

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed at the St Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as a defined version of epithalamin, a bovine pineal gland extract studied in the Soviet Union since the 1970s. It is best known for a 2003 report that it switched on telomerase in cultured human fibroblasts, and for mouse studies reporting longer maximum lifespan. In the UK it is sold as a research chemical for laboratory use only and has no MHRA marketing authorisation.

The claims around epitalon are larger than the evidence behind them, so this guide separates what was actually measured from what has been inferred: the cell-culture telomerase work, the animal lifespan and tumour data, the human cohort study that is usually cited without its caveats, and what UK researchers should check before buying.

What is epitalon?

Epithalamin was one of a family of tissue extracts the Khavinson group called peptide bioregulators, on the theory that each organ produces short peptides that regulate gene expression in its own cells. Analysing the pineal extract, the group identified a four-residue sequence, alanine-glutamate-aspartate-glycine, and synthesised it as epitalon in the 1990s. The intent was a reproducible molecule that could stand in for a variable animal-derived extract.

The proposed mechanism is that very short peptides enter the nucleus, bind to specific DNA sequences or histones and alter transcription. The Khavinson group has published molecular-modelling and cell-culture papers in support of this, and it is a plausible idea, but it has not been independently confirmed for epitalon by groups outside that network. This is a recurring theme: almost the entire epitalon literature comes from one institute and its collaborators.

Epitalon and telomerase: the 2003 fibroblast study

The paper most often cited is Khavinson, Bondarev and Butyugov, 'Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells', published in the Bulletin of Experimental Biology and Medicine in 2003. The authors added epitalon to cultures of human foetal fibroblasts that do not normally express telomerase and reported expression of the catalytic subunit hTERT, measurable telomerase enzyme activity, and telomeres roughly 2.4 times longer than in untreated cells.

A 2004 follow-up from the same group reported that treated fibroblasts kept dividing past the 44th passage while controls stopped at the 34th, which they interpreted as the peptide pushing cells beyond the Hayflick limit. In 2025, a preprint from a separate group reported increased telomere length in several human cell lines, attributed to either telomerase up-regulation or the alternative lengthening of telomeres (ALT) pathway depending on the line. At the time of writing that work has not completed peer review.

Two points of caution apply. First, the 2003 study was small, used foetal rather than adult cells, and its methods are briefly described. Second, telomerase activation is a double-edged result: telomerase is expressed in roughly 85 to 90% of human cancers, and a compound that reliably switched it on in somatic cells would raise safety questions before it raised hopes. The tumour data below is therefore not a side issue but central to how the telomerase claim should be read.

Mouse lifespan and tumour studies

The best-documented animal work is Anisimov, Khavinson and colleagues in Biogerontology (2003), which followed female Swiss-derived SHR mice given epitalon from a young age until natural death. The findings are more modest than they are usually summarised. Mean lifespan was not changed. The lifespan of the last 10% of survivors rose by 13.3% and maximum lifespan by 12.3%. Total spontaneous tumour incidence was unchanged, though leukaemia incidence was reported to be six-fold lower in treated animals. Food intake and body weight were unaffected.

Related studies from the same team reported reduced spontaneous mammary tumour development in HER-2/neu transgenic mice, reduced tumour incidence in female C3H/He mice, and effects on lifespan in senescence-accelerated mice compared with melatonin. In older rhesus monkeys, epitalon was reported to partially restore night-time melatonin secretion, which is consistent with a pineal origin but is not itself a longevity outcome.

The human cohort study, and why it is not what it looks like

Khavinson and Morozov's 2003 paper 'Peptides of pineal gland and thymus prolong human life' in Neuroendocrinology Letters is the source of the widely repeated claim that epitalon reduces mortality in the elderly. It followed 266 people aged over 60 for six to twelve years and reported mortality 1.6 to 1.8 times lower in those treated with the pineal peptide, with larger differences when thymalin, a thymus extract, was added.

Three things are routinely omitted when this study is cited. The peptide given was epithalamin, the bovine extract, not the synthetic tetrapeptide epitalon. Allocation was not randomised: the treated participants were patients of the institute and affiliated clinics, while comparison figures came from background mortality in the same population. And the paper has never been replicated outside Russia. It is a hypothesis-generating observation, not a controlled trial, and no regulator would accept it as evidence of benefit.

How epitalon is used in laboratory research

Because the central claims concern telomere biology and gene expression, most legitimate research applications are cell-based. Typical designs include:

• Telomerase activity (TRAP) and telomere-length assays in primary fibroblasts or cell lines, ideally with an attempt to replicate the 2003 findings in adult cells.
• Transcriptomic studies testing whether the tetrapeptide alters expression of hTERT, clock genes or pineal-related genes.
• Ageing models in rodents or invertebrates, following the Anisimov protocols, with tumour incidence as a mandatory endpoint.
• Comparative studies alongside other compounds studied in ageing research, such as the mitochondrial peptides MOTS-c and SS-31 or NAD+ precursors.
• Stability and analytical work: as a four-residue peptide, epitalon is straightforward to characterise by HPLC and mass spectrometry, which makes it a useful reference compound.

Is epitalon legal in the UK?

Yes. Epitalon is legal to buy, sell and possess in the UK as a research chemical. It is not a controlled substance under the Misuse of Drugs Act 1971 and it is not covered by the Psychoactive Substances Act 2016. It has no MHRA marketing authorisation, so supplying it for human medicinal use, or marketing it with anti-ageing medicinal claims, is unlawful under the Human Medicines Regulations 2012. That is why UK suppliers sell it strictly for research and why this article reports the literature rather than making claims about any product.

What to check before you buy epitalon in the UK

A four-amino-acid peptide is cheap and easy to synthesise, which makes the market crowded and quality inconsistent. The short sequence also means that a single deletion or a wrong protecting-group step produces a molecule that is easy to mistake for the real thing on a crude assay. Batch-level testing is the only reliable check.

1. Ask for a batch-specific certificate of analysis showing HPLC purity and mass-spectrometry identity confirming the Ala-Glu-Asp-Gly sequence. Calibre pens are tested by Janoshik Analytical and COAs are published on the site's COA page.
2. Confirm the stated quantity is peptide content. Calibre's epitalon pen is a 10mg pen.
3. Look for a purity target above 99%; acetate counter-ion and water content should be stated or accounted for.
4. Store refrigerated and protected from light, and record the batch date in your lab notebook.
5. Prefer pre-filled, precision-made pens if your workflow benefits from consistent volumes rather than reconstituting powder.

Summary

Epitalon is an interesting research compound with a coherent story: a defined pineal tetrapeptide, telomerase activation in cultured fibroblasts, and modest maximum-lifespan gains in mice. It is also a textbook case of evidence that has been over-read. The human mortality data used a different substance and no control group, nearly everything comes from a single institute, and telomerase activation is as much a safety question as a promise. For UK researchers it is legal to buy as a research chemical, and the priority is a proper certificate of analysis and a study design that can actually test the claims.